Carcinoid tumors of the gastrointestinal tract are slow-growing cancers that arise from special hormone-producing cells scattered throughout the digestive system. Although rare, these tumors require careful management that depends on their location, size, and whether they have spread. Treatment aims to remove the tumor, control hormone-related symptoms, and improve quality of life through a combination of surgery, medications, and emerging therapies being tested in research studies.

Understanding Treatment Goals for Gastrointestinal Carcinoid Tumors

When someone receives a diagnosis of a gastrointestinal carcinoid tumor, the treatment path ahead depends on many individual factors. The main goals of treatment focus on removing or reducing the tumor, managing symptoms caused by excess hormones, and maintaining the best possible quality of life. These tumors behave differently from person to person, so doctors must consider where the tumor started, how large it has grown, and whether it has spread to other organs like the liver or lymph nodes.^[1][2]

Treatment decisions also take into account the patient’s overall health, age, and personal preferences. Because many carcinoid tumors grow slowly, some patients may live for years with their condition. This means that treatment strategies must balance aggressive intervention with maintaining comfort and function in daily life. For some people, the tumor is discovered accidentally during surgery for another reason, while others may experience symptoms that lead to diagnosis.^[3][6]

Medical societies and cancer centers have developed standard treatment guidelines based on decades of experience and research. At the same time, scientists continue to explore new therapies through clinical trials. These studies test innovative drugs and approaches that may offer better outcomes or fewer side effects than current options. Patients diagnosed with gastrointestinal carcinoid tumors may have access to both established treatments approved by regulatory authorities and experimental therapies available through research protocols.^[4][7]

The treatment journey often involves a team of specialists including surgical oncologists, medical oncologists, gastroenterologists, and other healthcare professionals. This multidisciplinary approach ensures that each patient receives comprehensive care tailored to their specific situation. The stage of the disease—meaning whether it remains localized or has metastasized—plays a crucial role in determining which treatments will be most effective.^[12]

Standard Treatment Approaches

Surgical Treatment

Surgery remains the primary treatment method for gastrointestinal carcinoid tumors and offers the best chance for cure when the tumor is localized. The extent of surgery depends on the tumor’s location and size. For small tumors in the appendix—one of the most common sites—simple removal of the appendix during an appendectomy is often sufficient. However, larger tumors or those that have invaded surrounding tissue may require more extensive procedures.^[9][10]

When carcinoid tumors occur in the small intestine, surgeons typically remove the affected section along with nearby lymph nodes. This approach, called a segmental resection, helps ensure that any tumor cells in the surrounding tissue are also removed. For rectal carcinoid tumors smaller than 2 centimeters that have not invaded deeply, local excision may be adequate. Larger rectal tumors often require more radical surgical procedures similar to those used for rectal cancer.^[12][15]

Even when the cancer has spread to the liver or other organs, surgery can still play an important role. Surgical debulking—removing as much tumor as possible—can help reduce symptoms and improve quality of life, especially for patients experiencing carcinoid syndrome. This syndrome occurs when tumors release large amounts of hormones into the bloodstream, causing symptoms like flushing, diarrhea, and difficulty breathing.^[11][15]

Somatostatin Analogs for Symptom Control

Somatostatin analogs are medications that mimic a natural hormone in the body and represent a cornerstone of medical treatment for carcinoid tumors. The most commonly used drugs in this class are octreotide and lanreotide. These medications work by binding to special receptors on tumor cells and blocking the release of hormones that cause carcinoid syndrome symptoms.^[15][22]

Octreotide can be given as a short-acting injection several times daily for immediate symptom relief, or as a long-acting formulation administered once monthly. Lanreotide is also available as a long-acting injection given every four weeks. These medications can significantly reduce diarrhea episodes and flushing attacks, allowing patients to maintain their normal activities. Beyond symptom control, some evidence suggests that somatostatin analogs may also slow tumor growth, though they are not considered curative.^[18][22]

The effectiveness of somatostatin analogs varies among patients. Doctors often order special imaging tests called octreotide scans to determine whether a patient’s tumor has the receptors needed for these medications to work. When somatostatin analogs successfully control symptoms, patients typically continue treatment long-term. Side effects are generally mild and may include injection site reactions, digestive upset, or gallstone formation over time.^[11][15]

Additional Medical Therapies

For patients whose symptoms are not adequately controlled by somatostatin analogs alone, several other medications may be added. Telostristat ethyl is a drug approved specifically for carcinoid syndrome diarrhea in patients who continue to have symptoms despite somatostatin analog therapy. It works by blocking an enzyme called tryptophan hydroxylase, which is involved in serotonin production. By reducing serotonin levels, telostristat can decrease the frequency and severity of diarrhea.^[15][18]

Non-specific anti-diarrheal medications like loperamide may also provide relief for some patients. Managing carcinoid diarrhea often requires a multi-pronged approach because diarrhea in these patients can have multiple causes beyond hormone excess, including changes in bile acid absorption or damage to the intestines from the tumor itself.^[18][24]

Interferon-alpha has been used in some cases, particularly when combined with somatostatin analogs. This medication stimulates the immune system and may help slow tumor growth while also reducing hormone production. However, interferon treatment can cause flu-like symptoms and other side effects that limit its use for some patients. Doctors carefully weigh the potential benefits against the side effects when considering this option.^[15]

Liver-Directed Therapies

When carcinoid tumors spread to the liver, specialized treatments targeting liver metastases become important. These interventional approaches include hepatic artery embolization, where blood flow to tumor-containing areas of the liver is blocked, essentially starving the tumors. Another technique called radiofrequency ablation uses heat to destroy tumor tissue. These procedures are typically performed by interventional radiologists and can help reduce tumor burden and hormone production when surgery is not feasible.^[10][15]

Chemotherapy

Traditional chemotherapy plays a limited role in treating gastrointestinal carcinoid tumors because these cancers generally grow slowly and do not respond as well to chemotherapy as faster-growing tumors. When chemotherapy is used, it typically involves combinations of drugs such as 5-fluorouracil and streptozocin. Response rates rarely exceed 30 percent, and when tumors do respond, the benefit is usually short-lived, lasting less than one year. For this reason, chemotherapy is generally reserved for cases where other treatments have failed or for more aggressive tumor types.^[15]

Treatment in Clinical Trials

Peptide Receptor Radionuclide Therapy

One of the most promising advances in treating neuroendocrine tumors including gastrointestinal carcinoids is peptide receptor radionuclide therapy, specifically using lutetium Lu 177 dotatate. This innovative treatment, marketed as Lutathera, combines a radioactive substance (lutetium-177) with a molecule that binds to somatostatin receptors on tumor cells. The radioactive component delivers targeted radiation directly to tumor cells throughout the body, causing less damage to healthy tissue than traditional radiation therapy.^[15]

Lutetium Lu 177 dotatate received approval from the U.S. Food and Drug Administration based on clinical trial results showing that patients who received this treatment experienced longer progression-free survival compared to those who received somatostatin analog therapy alone. In one key study, approximately 16 percent of patients experienced complete or partial tumor shrinkage. The treatment is administered through intravenous infusion, typically given every eight weeks for a total of four doses.^[15]

Patients must meet certain criteria to receive this therapy. Their tumors need to have somatostatin receptors, which is confirmed through special imaging tests. Additionally, patients should have adequate kidney and bone marrow function because the radioactive treatment can affect these organs. Side effects may include nausea, vomiting, fatigue, and in some cases, effects on blood cell production or kidney function. Careful monitoring during and after treatment helps manage these potential complications.^[15]

Targeted Therapy with Everolimus

Everolimus represents another important option being used in advanced neuroendocrine tumors. This medication belongs to a class of drugs called mTOR inhibitors. The mTOR pathway is a cellular signaling system that regulates cell growth and division. By blocking this pathway, everolimus can slow or stop tumor growth without using traditional chemotherapy.^[15]

Clinical trials have tested everolimus in combination with octreotide long-acting repeatable (LAR) for patients with advanced neuroendocrine tumors associated with carcinoid syndrome. Results from a randomized Phase III trial showed that this combination improved progression-free survival compared to treatment with octreotide alone. This means patients lived longer without their disease worsening when everolimus was added to their somatostatin analog therapy.^[15]

Everolimus is taken as an oral tablet once daily, making it convenient for long-term use. Side effects can include mouth sores, rash, fatigue, diarrhea, and effects on blood sugar and cholesterol levels. Because everolimus suppresses the immune system, patients may have an increased risk of infections. Regular blood tests help doctors monitor for these effects and adjust treatment as needed. The medication is typically continued as long as it continues to provide benefit and side effects remain manageable.

Clinical Trials and Research Studies

Many patients with gastrointestinal carcinoid tumors participate in clinical trials testing new therapies or combinations of existing treatments. These trials occur in phases, each designed to answer specific questions about a treatment’s safety and effectiveness. Phase I trials primarily assess safety and determine the appropriate dose of a new drug. Phase II trials evaluate whether the treatment shows evidence of working against the cancer. Phase III trials compare the new treatment to current standard therapy to determine if it offers advantages.^[4][7]

Researchers are exploring various novel approaches in clinical trials. Some studies investigate newer chemotherapy drugs like gemcitabine, taxanes, or irinotecan, either alone or in combination with other agents. While traditional chemotherapy has shown limited benefit for carcinoid tumors, these newer drugs may work differently. Other trials examine different schedules or combinations of approved medications to see if outcomes can be improved.^[15]

Immunotherapy represents an area of active investigation. These treatments harness the body’s immune system to recognize and attack cancer cells. While immunotherapy has revolutionized treatment for some cancer types, its role in neuroendocrine tumors is still being defined through ongoing clinical trials. Patients interested in these experimental approaches should discuss with their oncologist whether they might be candidates for available trials.^[4]

Clinical trials for neuroendocrine tumors are conducted at major cancer centers across the United States, Europe, and other regions. Eligibility requirements vary depending on the specific trial but often include factors like the extent of disease, prior treatments received, and overall health status. Participation in clinical trials gives patients access to potentially beneficial new treatments before they become widely available, while also contributing to medical knowledge that may help future patients.

Most common treatment methods

• Surgical resection
  • Removal of the primary tumor and affected tissue, which is the standard therapeutic approach for localized carcinoid tumors
  • Appendectomy for tumors smaller than 1 centimeter in the appendix
  • Segmental resection of small intestine with removal of nearby lymph nodes
  • Local excision for small rectal tumors, or more radical surgery for larger tumors over 2 centimeters
  • Surgical debulking to reduce tumor burden even when complete removal is not possible
• Somatostatin analog therapy
  • Octreotide and lanreotide medications that block hormone release and control carcinoid syndrome symptoms
  • Available as short-acting injections for immediate relief or long-acting formulations given monthly
  • May also slow tumor growth in addition to controlling symptoms like diarrhea and flushing
  • Generally well-tolerated with mild side effects including injection site reactions and digestive upset
• Peptide receptor radionuclide therapy
  • Lutetium Lu 177 dotatate (Lutathera) delivers targeted radiation to tumor cells with somatostatin receptors
  • Shown to improve progression-free survival and cause tumor shrinkage in clinical trials
  • Administered as four intravenous infusions given every eight weeks
  • Approved by FDA for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors
• Targeted therapy
  • Everolimus, an mTOR inhibitor taken as daily oral tablet, slows tumor growth
  • Improves progression-free survival when combined with octreotide LAR in advanced disease
  • Telostristat ethyl specifically targets carcinoid syndrome diarrhea by reducing serotonin production
• Liver-directed therapies
  • Hepatic artery embolization blocks blood flow to liver metastases
  • Radiofrequency ablation uses heat to destroy tumor tissue in the liver
  • Performed by interventional radiologists when surgery is not feasible
• Supportive medications
  • Anti-diarrheal agents like loperamide for symptom management
  • Interferon-alpha may be used in combination with somatostatin analogs
  • Chemotherapy with 5-fluorouracil and streptozocin reserved for specific cases